SYK and cancer: Taken together with these earlier observations, the amplified expression of SYK in the poor prognosis KMT2A/MLL-R+ ALL patients prompts the hypothesis that SYKi may help overcome the cancer drug resistance of relapse clones and thereby provide the foundation for more effective multi-modality treatment regimens for KMT2A/MLL-R+ acute leukemias.